CA2214841A1 - Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites - Google Patents

Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites

Info

Publication number
CA2214841A1
CA2214841A1 CA002214841A CA2214841A CA2214841A1 CA 2214841 A1 CA2214841 A1 CA 2214841A1 CA 002214841 A CA002214841 A CA 002214841A CA 2214841 A CA2214841 A CA 2214841A CA 2214841 A1 CA2214841 A1 CA 2214841A1
Authority
CA
Canada
Prior art keywords
cells
rho family
growth
rho
family members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002214841A
Other languages
English (en)
Inventor
Lisa Mckerracher
Maxime Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002214841A priority Critical patent/CA2214841A1/fr
Priority to AU97321/98A priority patent/AU9732198A/en
Priority to PCT/CA1998/001013 priority patent/WO1999023113A2/fr
Priority to CA002304981A priority patent/CA2304981A1/fr
Priority to EP98951138A priority patent/EP1049715A2/fr
Publication of CA2214841A1 publication Critical patent/CA2214841A1/fr
Priority to US11/948,514 priority patent/US20080233098A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002214841A 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites Withdrawn CA2214841A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002214841A CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
AU97321/98A AU9732198A (en) 1997-10-31 1998-11-02 Rho family antagonists and their use to block inhibition of neurite outgrowth
PCT/CA1998/001013 WO1999023113A2 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites
CA002304981A CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites
EP98951138A EP1049715A2 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites
US11/948,514 US20080233098A1 (en) 1997-10-31 2007-11-30 RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002214841A CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites

Publications (1)

Publication Number Publication Date
CA2214841A1 true CA2214841A1 (fr) 1999-04-30

Family

ID=4161412

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002214841A Withdrawn CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
CA002304981A Abandoned CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002304981A Abandoned CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites

Country Status (4)

Country Link
EP (1) EP1049715A2 (fr)
AU (1) AU9732198A (fr)
CA (2) CA2214841A1 (fr)
WO (1) WO1999023113A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002410A (es) 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
CA2325842C (fr) 2000-11-02 2007-08-07 Lisa Mckerracher Methodes de production et d'administration de preparations combinant un antagoniste de rho et un adhesif tissulaire aux systemes nerveux central et peripherique blesses de mammiferes et utilisations de ces preparations
CN101310771B (zh) 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
CA2367636C (fr) * 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
WO2003030836A2 (fr) 2001-10-12 2003-04-17 Case Western Reserve University Regeneration neuronale
EP1465900B1 (fr) 2002-01-10 2008-05-14 Bayer HealthCare AG Inhibiteurs de la rho-kinase
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
CA2513584A1 (fr) * 2003-01-20 2004-08-05 Vib Vzw Utilisation de proteines yop ou d'inhibiteurs rho gtpase comme inhibiteurs de caspase-1
CA2556589A1 (fr) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. Derives de piperidine substitues en position 4
ZA200804497B (en) 2005-12-22 2009-10-28 Alcon Res Ltd (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
EP2177218A1 (fr) * 2008-10-15 2010-04-21 Medizinische Universität Wien Thérapie régénératrice
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US9687483B2 (en) 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) * 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
AU7564396A (en) * 1995-11-16 1997-06-05 Ciba-Geigy Ag Rac-proteine kinase as therapeutic agent or in diagnostics
US6060297A (en) * 1997-04-17 2000-05-09 Incyte Pharmaceuticals, Inc. Rho protein
CA2300878A1 (fr) * 1997-08-13 1999-02-25 Yale University Regeneration d'axones dans le systeme nerveux central

Also Published As

Publication number Publication date
WO1999023113A3 (fr) 1999-08-26
AU9732198A (en) 1999-05-24
WO1999023113A2 (fr) 1999-05-14
EP1049715A2 (fr) 2000-11-08
CA2304981A1 (fr) 1999-05-14

Similar Documents

Publication Publication Date Title
CA2214841A1 (fr) Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
US20070128585A1 (en) (+)-trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
Tang Inhibitors of neuronal regeneration: mediators and signaling mechanisms
Liu et al. Extracellular regulators of axonal growth in the adult central nervous system
US8932821B2 (en) NOGO receptor binding protein
Hendrix et al. Role of intermediate filaments in migration, invasion and metastasis
RU2304585C2 (ru) Очищенный иммуногенный белок, его фрагменты и производные
KR100828058B1 (ko) Ｎｏｇｏ 수용체가 매개하는 축삭 성장의 차단
Yabe et al. Phospho‐dependent association of neurofilament proteins with kinesin in situ
Ivins et al. Cerebroglycan, a developmentally regulated cell-surface heparan sulfate proteoglycan, is expressed on developing axons and growth cones
KR100196540B1 (ko) 축색성장 조절인자
US20050256052A1 (en) Method of modulating tissue growth using Frzb protein
WO1995022344A1 (fr) Utilisation therapeutique de glycoproteines associees a la myeline (gam)
WO1998022499A9 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
WO1998022499A2 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
US20030113325A1 (en) Reducing myelin-mediated inhibition of axon regeneration
WO2002083182A2 (fr) Effect du facteur sigma de la tyrosine phosphatase de la proteine receptrice (rptp-$g(s)) sur la regeneration des axones neurales et modification de la synapse
JP2006525784A (ja) 膜貫通型タンパク質ａｍｉｇｏおよびその用途
JPH11509089A (ja) ｐ５３と転写因子ＤＰ−１との相互作用
US20080233098A1 (en) RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
KR100740207B1 (ko) Ｔｅｍ７ 및 니도젠을 유효성분으로 함유하는 약학 조성물
Yu Purification and Functional Characterization of Recombinant Human ADAM8 protease
Delves VASE Isoform of Neural Cell Adhesion Molecule Protein: Distribution, Sub Cellular Localisation and Functional Effect on Cell Morphology
GRUNWALD Development and Disease
Scott The role of p75NTR in axonal regeneration and intraspinal plasticity following spinal deafferentation

Legal Events

Date Code Title Description
AZWI Withdrawn application